Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Abstract

BACKGROUND Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. OBJECTIVE Our aim was to assess the response to ixekizumab in patients with moderate-to-severe plaque psoriasis who did not… (More)
DOI: 10.1007/s40257-016-0246-9

5 Figures and Tables

Topics

  • Presentations referencing similar topics